Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.
/PRNewswire/ Regulatory filing recently submitted in the European Union Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food.
/PRNewswire/ Third quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million attributable to REGEN-COV®(2) Third.
A study suggests the treatment triggers the body s immune system to attack cancer cells. A trial found medication led to a reduction, and in some cases the disappearance, of some tumours